ADXS vs. BFRI, INDP, NLSP, SNGX, MTVA, ENSC, APLM, GTBP, FRTX, and ADIL
Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Biofrontera (BFRI), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), Soligenix (SNGX), MetaVia (MTVA), Ensysce Biosciences (ENSC), Apollomics (APLM), GT Biopharma (GTBP), Fresh Tracks Therapeutics (FRTX), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry.
Ayala Pharmaceuticals vs.
Ayala Pharmaceuticals (NASDAQ:ADXS) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.
Biofrontera received 9 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 69.23% of users gave Biofrontera an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
Ayala Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.
Ayala Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Ayala Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.
Biofrontera has a consensus target price of $2.75, suggesting a potential upside of 329.82%. Given Biofrontera's stronger consensus rating and higher probable upside, analysts plainly believe Biofrontera is more favorable than Ayala Pharmaceuticals.
Biofrontera has higher revenue and earnings than Ayala Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Biofrontera had 5 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 6 mentions for Biofrontera and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Biofrontera's score of -0.82 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media.
Summary
Biofrontera beats Ayala Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Ayala Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ayala Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ADXS) was last updated on 5/27/2025 by MarketBeat.com Staff
